|
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
RECRUITINGPhase 1/2Sponsored by Betta Pharmaceuticals Co., Ltd.
Actively Recruiting
PhasePhase 1/2
SponsorBetta Pharmaceuticals Co., Ltd.
Started2026-01-29
Est. completion2028-12-28
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07435038
Summary
Evaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Histologically confirmed advanced solid tumor with RAS mutations identified through deoxyribonucleic acid (DNA) sequencing. * Have received prior standard therapy appropriate for tumor type and stage. * Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Adequate organ function. Exclusion Criteria: * Primary central nervous system (CNS) tumors active and untreated brain metastases. * Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication. * History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy
Conditions6
Advanced Solid TumorsCancerColorectal Cancer (CRC)Lung CancerNon-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions1
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 1/2
SponsorBetta Pharmaceuticals Co., Ltd.
Started2026-01-29
Est. completion2028-12-28
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07435038